Financial Performance - Revenue from contracts with customers was CHF 0 for the three months ended June 30, 2025, compared to CHF 115,277 for the same period in 2024, indicating a decrease of 100%[5]. - Operating loss for the six months ended June 30, 2025, was CHF 1,339,160, a reduction of 20.7% compared to CHF 1,687,408 for the same period in 2024[5]. - Net loss from continuing operations for the six months ended June 30, 2025, was CHF 3,431,775, compared to CHF 2,191,939 for the same period in 2024, reflecting an increase of 56.7%[5]. - The company reported a net loss of CHF 1,841,165 for the three months ended June 30, 2025, compared to a profit of CHF 12,878,632 for the same period in 2024, indicating a significant shift in performance[7]. - The total comprehensive loss for the six months ended June 30, 2025, was CHF 3,260,809, compared to a profit of CHF 9,690,375 for the same period in 2024[7]. - The company reported a basic and diluted loss per share of CHF 0.03 for the six months ended June 30, 2025, compared to a profit of CHF 0.10 for the same period in 2024[5]. - For the six months ended June 30, 2025, Addex Therapeutics reported a net loss of CHF 3,314,028 compared to a net profit of CHF 9,791,493 for the same period in 2024[21]. - The total comprehensive loss for the period was CHF 1,406,841, reflecting a decrease from the previous year's profit[16]. - The net loss from continuing operations was CHF 1,958,912 for the three months ended June 30, 2025, compared to CHF 1,456,761 for the same period in 2024, representing an increase of approximately 34.4%[109]. - The net profit from discontinued operations for the three months ended June 30, 2025, was CHF 117,747, a significant decrease from CHF 14,335,393 in 2024[109]. - The net loss attributable to equity holders of the company for the six months ended June 30, 2025, was CHF 3,314,028, compared to a profit of CHF 9,791,493 in 2024, indicating a shift in performance[109]. Assets and Liabilities - Total assets decreased to CHF 8,506,015 as of June 30, 2025, down from CHF 10,678,303 as of December 31, 2024, representing a decline of approximately 20.4%[4]. - Total current liabilities increased to CHF 1,150,446 as of June 30, 2025, from CHF 802,093 as of December 31, 2024, marking a rise of 43.4%[4]. - Cash and cash equivalents decreased to CHF 2,300,994 as of June 30, 2025, down from CHF 3,341,738 as of December 31, 2024, a decline of 31.1%[4]. - The total equity as of June 30, 2025, was CHF 7,212,726, down from CHF 12,651,300 as of June 30, 2024[16]. - Trade payables rose significantly to CHF 640,087 as of June 30, 2025, compared to CHF 253,290 as of December 31, 2024, indicating a substantial increase in liabilities[61]. - Other current assets increased to CHF 356,586 as of June 30, 2025, from CHF 199,625 as of December 31, 2024, primarily due to higher prepayments[57]. - The net book value of right-of-use assets decreased to CHF 37,555 as of June 30, 2025, from CHF 41,578 as of December 31, 2024[58]. - The Group's long-lived assets in Switzerland decreased from $7,136,602 on December 31, 2024, to $5,848,099 on June 30, 2025[53]. Cash Flow and Investments - Cash and cash equivalents at the end of the period were CHF 2,300,994, down from CHF 3,787,780 at the end of June 2024[21]. - The Group's cash flow from discontinued activities for the six months ended June 30, 2025, was CHF 57,673, compared to CHF 1,597,232 in the same period of 2024[97]. - The Group invested CHF 795,029 in Stalicla Ltd in June 2025, receiving 23,342 preferred shares and derivative financial instruments[114]. - The Group's financial assets at fair value through other comprehensive income included preferred shares of Stalicla SA, classified for strategic purposes rather than trading[101]. - The Group's total financial assets measured at fair value as of June 30, 2025, amounted to CHF 795,029, with various derivative financial instruments included in this valuation[104]. Operating Costs - Total operating costs for the three months ended June 30, 2025, were CHF 769,273, a decrease of 24.1% compared to CHF 1,014,593 for the same period in 2024[54]. - Total operating costs recognized as continuing operating costs for the six-month period ended June 30, 2025, decreased by CHF 590,005 to CHF 1,446,590 compared to CHF 2,037,595 for the same period in 2024[86]. - The total external research and development costs for the six-month period ended June 30, 2025, were CHF 101,075, a decrease from CHF 363,571 in the same period of 2024[86]. - The total share-based compensation expense for the six-month period ended June 30, 2025, was CHF 44,098, down from CHF 105,572 for the same period in 2024[68]. - Staff costs for the six-month period ended June 30, 2025, remained stable at CHF 145,538 compared to CHF 136,641 for the same period in 2024[90]. Strategic Focus and Transactions - Addex Therapeutics has a 20% equity interest in Neurosterix US Holdings LLC, which is part of its strategic focus on neurological disorders[23]. - The Group recognized discontinued operations related to the sale of its allosteric modulator drug discovery technology platform on April 2, 2024[33]. - The Group divested its allosteric modulator drug discovery technology platform and preclinical programs to Neurosterix Pharma Sàrl for gross proceeds of CHF 5.0 million and a 20% equity interest valued at CHF 9.4 million[93][99]. - The Group entered into a service agreement with Neurosterix Pharma Sàrl to access certain staff and infrastructure at zero cost until December 31, 2024, ensuring continuity of retained business operations[93]. - The Group's share of net loss from Neurosterix Group for the six months ended June 30, 2025, was CHF 2,079,296, reflecting ongoing R&D and administrative expenses[100]. Grants and Funding - The Group received a grant of CHF 0.5 million from Eurostars/Innosuisse to support the mGlu2 NAM program, with CHF 0.3 million received in December 2023[85]. - The Group recognized CHF 0.1 million and CHF 0.3 million as revenue in continuing operations related to the research agreement for the three-month and six-month periods ended June 30, 2024[79]. Management and Shareholder Information - Key management compensation for the three months ended June 30, 2025, totaled CHF 118,774, slightly down from CHF 142,302 in 2024, indicating a decrease of about 16.5%[110]. - As of June 30, 2025, the number of outstanding shares was 141,192,292, excluding 43,162,204 treasury shares[63]. - The weighted average number of shares in issue increased to 100,523,234 for the three months ended June 30, 2025, from 98,305,583 in 2024, reflecting a growth of approximately 2.2%[109]. - From July 1, 2025, to the issuance date of the financial statements, the Group sold 5,086,552 shares at an average price of CHF 0.069, generating total gross proceeds of CHF 350,427[115].

Core Viewpoint - Addex Therapeutics reported significant progress in drug development and business milestones during the first half of 2025, particularly with its GABAB PAM drug candidate for chronic cough and the mGlu2 PAM asset ADX71149 [2][5][16] Financial Performance - Income for H1 2025 decreased to CHF 107,000 from CHF 350,000 in H1 2024, a decline of CHF 243,000 [4] - R&D expenses reduced to CHF 391,000 in H1 2025 from CHF 584,000 in H1 2024, reflecting a decrease of CHF 193,000 [4][8] - G&A expenses decreased to CHF 1,056,000 in H1 2025 from CHF 1,453,000 in H1 2024, a reduction of CHF 397,000 [4][9] - Total operating loss improved to CHF 1,340,000 in H1 2025 from CHF 1,687,000 in H1 2024, an improvement of CHF 347,000 [4] - Net loss from continuing operations increased to CHF 3,432,000 in H1 2025 from CHF 2,192,000 in H1 2024, an increase of CHF 1,240,000 [4][10] - Basic and diluted loss per share was CHF 0.03 for H1 2025 compared to a profit of CHF 0.10 for H1 2024 [11] Cash Position - Cash and cash equivalents decreased to CHF 2.3 million as of June 30, 2025, down from CHF 3.8 million as of June 30, 2024, a decrease of CHF 1.5 million [7][11] Corporate Developments - The GABAB PAM chronic cough candidate showed robust anti-tussive activity in multiple disease models [5][6] - The company regained rights to the Phase 2 mGlu2 PAM asset, ADX71149, and is evaluating next steps internally [2][5] - An option agreement was entered with Sinntaxis for exclusive licensing of intellectual property related to mGlu5 NAM in brain injury recovery [2][5] - Indivior successfully advanced its GABAB PAM program for substance use disorders through IND enabling studies [5][6] - The company invested in Stalicla, reinforcing its commitment to innovative treatments for CNS disorders [2][5][16]

Core Viewpoint - Addex Therapeutics reported significant progress in drug development and business milestones during the first half of 2025, particularly with its GABAB PAM drug candidate for chronic cough and the mGlu2 PAM asset ADX71149 [2][5][16] Financial Performance - Income for H1 2025 decreased to CHF 107,000 from CHF 350,000 in H1 2024, a decline of CHF 243,000 [4] - R&D expenses reduced to CHF 391,000 in H1 2025 from CHF 584,000 in H1 2024, an improvement of CHF 193,000 [4][8] - G&A expenses decreased to CHF 1,056,000 in H1 2025 from CHF 1,453,000 in H1 2024, a reduction of CHF 397,000 [4][9] - Total operating loss improved to CHF 1,340,000 in H1 2025 from CHF 1,687,000 in H1 2024, a decrease of CHF 347,000 [4] - Net loss from continuing operations increased to CHF 3,432,000 in H1 2025 from CHF 2,192,000 in H1 2024, an increase of CHF 1,240,000 [4][10] - Basic and diluted loss per share was CHF 0.03 for H1 2025 compared to a profit of CHF 0.10 for H1 2024 [7][11] - Cash position decreased to CHF 2.3 million at the end of H1 2025 from CHF 3.8 million at the end of H1 2024 [5][11] Operational Highlights - The GABAB PAM chronic cough candidate showed robust anti-tussive activity in multiple disease models [5][6] - Rights to the Phase 2 mGlu2 PAM asset, ADX71149, were regained, with internal evaluations for next steps ongoing [2][5] - Indivior successfully advanced its GABAB PAM program for substance use disorders through IND enabling studies [5][6] - An option agreement was entered with Sinntaxis for exclusive licensing of intellectual property related to mGlu5 NAM in brain injury recovery [5][6] - Investment in Stalicla SA was made, reinforcing the commitment to innovative treatments for CNS disorders [5][6][16]

Core Viewpoint - Addex Therapeutics is set to report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025, followed by a conference call on October 1, 2025, to discuss the results and provide a business update [1][2]. Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3]. - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [3]. - Addex has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders, which has completed IND enabling studies [3]. - The company is also advancing an independent GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions [3]. Upcoming Events - The conference call to discuss the financial results will take place on October 1, 2025, at 16:00 CEST, with participation from CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev [1][2].

Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3] - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [3] - Addex has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders, which has completed IND enabling studies [3] - The company is also advancing an independent GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions [3] Recent Developments - Addex Therapeutics announced the appointment of the Bank of New-York Mellon (BNY) as its new ADS depositary agent, effective October 6, 2025 [1] - The appointment of BNY will not impact the fees paid by ADS holders, and no action is required from them at the effective date [2] Stock Information - Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares are listed on the NASDAQ Capital Market under the ticker symbol "ADXN" [3]

Core Insights - Addex Therapeutics has made a strategic investment of CHF 2 million in Stalicla, a company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders [1][2] - The investment aims to support Stalicla's portfolio of autism-focused drug candidates and its series C financing, while also enhancing Addex's commitment to advancing innovative treatments for CNS disorders [2][3] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, with a lead drug candidate, dipraglurant, under evaluation for brain injury recovery [4] - Stalicla has raised over $50 million in equity and more than $30 million in non-dilutive funding, focusing on transforming treatments for neurodevelopmental disorders [3][4] Investment Details - The investment will enable Stalicla to advance its lead autism candidate STP1 and a second asset into Phase 2 trials, targeting specific subpopulations within autism spectrum disorder (ASD) [2][3] - Stalicla is also progressing its STP7 program (mavoglurant) for cocaine use disorders, which is the most advanced treatment candidate in development for this indication [2][3] Leadership Changes - As part of the investment, Addex CEO Tim Dyer has been appointed to Stalicla's Board of Directors and nominated as Chairman, indicating a deeper collaboration between the two companies [1][2]

Core Insights - Stalicla SA has successfully closed a CHF 2 million financing round led by Addex Therapeutics to advance its precision medicine programs for neurodevelopmental disorders [1][2] - The financing will support Stalicla's operations and program development as it prepares for a Series C financing and partnerships for key programs [1][2] - Stalicla's DEPI precision neuro platform and its autism assets, STP1 and STP2, have garnered investor confidence, while the STP7 program (mavoglurant) is progressing towards Phase 3 trials [1][3] Company Overview - Stalicla SA is a clinical-stage biopharmaceutical company based in Switzerland, having raised over $50 million in equity and more than $30 million in non-dilutive funding to enhance treatments for neurodevelopmental disorders [3] - The company has developed a neuro precision development platform that identifies stratified patient subgroups, facilitating personalized treatment options [3] - Stalicla is preparing to initiate Phase 2 trials for its leading asset, STP1, targeting specific subpopulations within autism, while STP7 is advancing towards Phase 3 trials with funding from the US government [3] Leadership and Strategic Direction - Tim Dyer has been appointed to the Board of Directors of Stalicla and nominated as Chairman, indicating a strategic partnership with Addex Therapeutics [2] - Lynn Durham, CEO of Stalicla, emphasized the importance of this financing in reaching significant milestones, including transformative clinical trials in autism and substance use disorders [2] - Addex Therapeutics recognizes Stalicla's platform as world-leading in precision medicine for neurodevelopmental disorders and aims to support the advancement of these critical medicines [2]

[Unaudited Interim Condensed Consolidated Financial Statements](index=2&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Financial%20Statements) [Unaudited Interim Condensed Consolidated Balance Sheets](index=2&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to CHF 9.5 million by March 31, 2025, driven by lower cash and investment values Consolidated Balance Sheet Summary (in Swiss francs) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Current Assets** | | | | Cash and cash equivalents | 2,825,484 | 3,341,738 | | Total current assets | 3,197,278 | 3,541,363 | | **Non-Current Assets** | | | | Investment accounted for using the equity method | 6,239,691 | 7,087,142 | | Total non-current assets | 6,287,376 | 7,136,940 | | **Total Assets** | **9,484,654** | **10,678,303** | | **Liabilities & Equity** | | | | Total current liabilities | 1,056,812 | 802,093 | | Total non-current liabilities | 132,164 | 198,939 | | **Total Equity** | **8,295,678** | **9,677,271** | | **Total Liabilities and Equity** | **9,484,654** | **10,678,303** | [Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss](index=3&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Loss) The company's net loss from continuing operations widened to CHF 1.47 million in Q1 2025 due to no revenue Statement of Comprehensive Loss Summary (in Swiss francs) | Account | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Revenue from contract with customer | - | 233,480 | | Operating loss | (606,262) | (788,092) | | Share of net loss of investment (equity method) | (847,451) | - | | **Net loss from continuing operations** | **(1,472,863)** | **(735,178)** | | Net loss from discontinued operations | - | (2,351,961) | | **Net loss for the period** | **(1,472,863)** | **(3,087,139)** | | **Total comprehensive loss for the period** | **(1,406,841)** | **(3,135,856)** | | Basic and diluted loss per share (Total) | (0.01) | (0.03) | [Unaudited Interim Condensed Consolidated Statements of Changes in Equity](index=4&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Equity) Total equity declined by CHF 1.38 million to CHF 8.30 million in Q1 2025, primarily due to the period's net loss Changes in Equity for Q1 2025 (in Swiss francs) | Description | Amount | | :--- | :--- | | **Balance as of January 1, 2025** | **9,677,271** | | Net loss for the period | (1,472,863) | | Other comprehensive income for the period | 66,022 | | Value of share-based services | 24,917 | | Net sales of treasury shares | 331 | | **Balance as of March 31, 2025** | **8,295,678** | [Unaudited Interim Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operations was CHF 0.6 million, leading to a quarter-end cash balance of CHF 2.8 million Statement of Cash Flows Summary (in Swiss francs) | Cash Flow Category | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | (598,706) | (2,194,379) | | Net cash from financing activities | 97,991 | 164,548 | | **Decrease in cash and cash equivalents** | **(500,715)** | **(2,029,831)** | | Cash and cash equivalents at beginning of period | 3,341,738 | 3,865,481 | | **Cash and cash equivalents at end of period** | **2,825,484** | **1,627,832** | [Unaudited Notes to the Interim Condensed Consolidated Financial Statements](index=7&type=section&id=Unaudited%20Notes%20to%20the%20Interim%20Condensed%20Consolidated%20Financial%20Statements) [General Information](index=7&type=section&id=1.%20General%20information) Addex is a Swiss clinical-stage biopharma firm developing allosteric modulators for neurological disorders - The company is a clinical-stage biopharmaceutical firm developing novel small molecule allosteric modulators for neurological disorders[14](index=14&type=chunk) - The company holds a 20% equity interest in Neurosterix US Holdings LLC, which was acquired as part of a major transaction[15](index=15&type=chunk) - The company's shares are traded on the SIX Swiss Exchange (ADXN) and its American Depositary Shares (ADSs) are traded on the Nasdaq Stock Market (ADXN)[16](index=16&type=chunk) [Material Accounting Estimates and Judgments](index=8&type=section&id=3.%20Material%20accounting%20estimates%20and%20judgments) Management highlights a material uncertainty about its going concern status, with cash funding operations only to mid-June 2026 - **Going Concern Warning:** A material uncertainty exists that raises substantial doubt about the Group's ability to continue as a going concern as existing cash is only expected to fund operations through mid-June 2026[22](index=22&type=chunk) - The business faces risks from health pandemics and geopolitical events that could disrupt clinical trials, supply chains, and the ability to raise capital[23](index=23&type=chunk) - The divestment of its drug discovery platform to Neurosterix in Q1 2024 is accounted for as a discontinued operation, for which it received a 20% equity interest[24](index=24&type=chunk)[25](index=25&type=chunk) [Segment Reporting](index=10&type=section&id=5.%20Segment%20reporting) The company operates as a single segment, with Q1 2025 income derived solely from services provided by Neurosterix - The company operates in a single operating segment: the discovery, development, and commercialization of small-molecule pharmaceutical products[33](index=33&type=chunk) Income by Major Counterparty (in Swiss francs) | Counterparty | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Indivior PLC | - | 233,480 | | Neurosterix Group | 71,055 | - | | Other counterparties | - | 1,430 | | **Total** | **71,055** | **234,910** | [Revenue from Contract with Customer](index=19&type=section&id=16.%20Revenue%20from%20contract%20with%20customer) The company recorded no revenue in Q1 2025, and Janssen terminated its license agreement for ADX71149 post-quarter - The research agreement with Indivior PLC generated no revenue in Q1 2025 as it was completed in 2024; in Q1 2024, it had recognized CHF 0.2 million[70](index=70&type=chunk) - **Janssen Agreement Terminated:** On April 17, 2025, Janssen terminated the license agreement for ADX71149 after a Phase 2a epilepsy trial failed its primary endpoint, returning all IP to Addex[72](index=72&type=chunk) - No revenue was recognized from the Janssen agreement in either Q1 2025 or Q1 2024[73](index=73&type=chunk) [Operating Costs](index=22&type=section&id=18.%20Operating%20costs) Total operating costs from continuing operations decreased by 34% to CHF 0.68 million due to lower R&D and professional fees - The decrease in operating costs was mainly driven by a CHF 0.1 million reduction in external R&D and a CHF 0.1 million reduction in professional fees[77](index=77&type=chunk) Operating Costs from Continuing Operations (in Swiss francs) | Cost Category | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | External research and development cost | 32,583 | 179,110 | | Professional fees | 302,382 | 452,010 | | Staff costs | 101,042 | 68,682 | | **Total operating costs** | **677,317** | **1,023,002** | [Discontinued Operations](index=23&type=section&id=21.%20Discontinued%20operations) The company divested its drug discovery platform to Neurosterix for CHF 5.0 million cash and a 20% equity stake - On April 2, 2024, the Group completed the divestment of its allosteric modulator drug discovery technology platform and preclinical programs to Neurosterix Pharma Sàrl[82](index=82&type=chunk) - As consideration for the transaction, Addex received gross proceeds of **CHF 5.0 million in cash and a 20% equity interest** in Neurosterix US Holdings LLC[82](index=82&type=chunk) Financial Performance of Discontinued Operations (in Swiss francs) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Operating loss | - | (1,917,978) | | Legal fees related to the sale | - | (428,311) | | **Total net loss from discontinued operations** | **-** | **(2,351,961)** | [Interests in Associates](index=25&type=section&id=22.%20Interests%20in%20associates) The carrying value of the company's 20% equity interest in Neurosterix decreased to CHF 6.24 million - The initial 20% equity interest in Neurosterix was valued at CHF 9.43 million on April 2, 2024; the loss recognized reflects R&D and G&A expenditures incurred by Neurosterix[90](index=90&type=chunk) Change in Carrying Amount of Investment in Neurosterix (in Swiss francs) | Description | Amount | | :--- | :--- | | Beginning of the period (Jan 1, 2025) | 7,087,142 | | Share of net loss of Neurosterix Group | (847,451) | | **End of the period (Mar 31, 2025)** | **6,239,691** | [Events After the Balance Sheet Date](index=27&type=section&id=25.%20Events%20after%20the%20balance%20sheet%20date) Post-quarter, Addex raised CHF 0.67 million from treasury share sales and Janssen terminated its ADX71149 license - From April 1, 2025, to the report's issuance date, the Group sold 11,094,913 treasury shares for **total gross proceeds of CHF 669,102**[97](index=97&type=chunk) - On April 17, 2025, Janssen terminated the license agreement for ADX71149, and the program was returned to the Group[97](index=97&type=chunk)

Core Viewpoint - Addex Therapeutics reported a strong start to 2025 with significant progress in product development and business milestones, particularly in their GABAB PAM drug candidate for chronic cough and regained rights to their Phase 2 mGlu2 PAM asset, ADX71149 [2][5]. Financial Summary - Income for Q1 2025 was CHF 71,000, a decrease of CHF 164,000 from CHF 235,000 in Q1 2024 [4]. - R&D expenses decreased to CHF 156,000 from CHF 245,000, a reduction of CHF 89,000 [4][8]. - G&A expenses decreased to CHF 521,000 from CHF 778,000, a reduction of CHF 257,000 [4][8]. - Total operating loss improved to CHF 606,000 from CHF 788,000, an improvement of CHF 182,000 [4]. - Net loss from continuing operations was CHF 1,473,000, compared to CHF 735,000 in Q1 2024, an increase of CHF 738,000 [4]. - Net loss for the period decreased to CHF 1,473,000 from CHF 3,087,000, a reduction of CHF 1,614,000 [4][9]. - Basic and diluted net loss per share was CHF 0.01, down from CHF 0.03 in the same period last year [4][10]. - Cash and cash equivalents increased to CHF 2.8 million from CHF 1.6 million, an increase of CHF 1.2 million [4][11]. - Shareholders' equity improved significantly to CHF 8.3 million from a negative CHF 1.4 million [4]. Operational Highlights - The GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in multiple disease models [5][6]. - The company regained rights to its Phase 2 mGlu2 PAM asset, ADX71149 [5][6]. - Indivior successfully advanced their GABAB PAM program for substance use disorders through IND enabling studies [5][6]. - An option agreement was entered with Sinntaxis for exclusive licensing of intellectual property related to mGlu5 NAM in brain injury recovery [5][6].

Group 1 - Addex Therapeutics will release its Q1 2025 Financial Results on June 19, 2025, followed by a business update and product pipeline review during a teleconference and webcast [1][2] - The teleconference will be held at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) [2] - Addex Therapeutics focuses on developing novel small molecule allosteric modulators for neurological disorders, with its lead drug candidate, dipraglurant, under evaluation for brain injury recovery [3] Group 2 - Addex's partner, Indivior, has selected a GABAB PAM drug candidate for substance use disorders and completed IND enabling studies [3] - The company is also advancing an independent GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions [3] - Addex shares are listed on the SIX Swiss Exchange and NASDAQ under the ticker symbol "ADXN" [3]